CAAS
SUPN icon

Capital Asset Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Capital Asset Advisory Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-120
Closed -$3K – 1404
2020
Q4 		$3K Buy
+120
New +$2.58K ﹤0.01% 1394

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Capital Asset Advisory Services's SUPN Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 120 shares — an estimated $3K sold.

Capital Asset Advisory Services first reported a position in SUPN in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 120 Supernus Pharmaceuticals shares in Q1 2021, an estimated $3K.
  • Capital Asset Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Supernus Pharmaceuticals position peaked at $3K in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.